KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Total Current Liabilities (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Total Current Liabilities for 4 consecutive years, with $168.5 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Total Current Liabilities rose 34.97% year-over-year to $168.5 million, compared with a TTM value of $168.5 million through Sep 2023, up 34.97%, and an annual FY2022 reading of $173.0 million, up 28.35% over the prior year.
  • Total Current Liabilities was $168.5 million for Q3 2023 at Ginkgo Bioworks Holdings, up from $163.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $191.7 million in Q1 2023 and bottomed at $1.4 million in Q1 2021.
  • Average Total Current Liabilities over 4 years is $118.3 million, with a median of $134.9 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities surged 11100.25% in 2022, then increased 20.38% in 2023.
  • Year by year, Total Current Liabilities stood at $73.2 million in 2020, then soared by 84.05% to $134.8 million in 2021, then rose by 28.35% to $173.0 million in 2022, then fell by 2.6% to $168.5 million in 2023.
  • Business Quant data shows Total Current Liabilities for DNA at $168.5 million in Q3 2023, $163.3 million in Q2 2023, and $191.7 million in Q1 2023.